Lysosomal Lipid Dysregulation in Parkinson’s Disease: Genetic and Medication Effects in CSF Metabolomics
Objective: Define lipid signatures in sporadic, LRRK2, and GBA1 PD and pre-manifest carriers and assess medication impacts. Background: Lysosomal dysfunction contributes to PD, particularly in…Biomarker Panels for Parkinson’s Disease using Multi-Omics Approach: Recent Developments and Future Directions
Objective: The main objective is to identify potential biomarker panels that may represent disease onset, progression, and risk factors for Parkinson's disease (PD). Background: PD…Sex Differences in α-Synuclein Seed Amplification Assay Parameters and Longitudinal Clinical Subtypes of Parkinson’s Disease
Objective: To investigate differences in baseline α-synuclein seed amplification assay (SAA) metrics and longitudinal clinical subtypes of Parkinson’s disease (PD) between the two biological sexes.…AntiSaccadeNet: A Deep Learning Framework for Differentiating Parkinsonian Disorders through Antisaccade Time Series Classification
Objective: To develop and evaluate a deep learning architecture (AntiSaccadeNet) that utilizes continuous antisaccade eye movement time-series data to differentiate between Parkinson's disease (PD) and…Sleep-wake modulation of subthalamic activity in patients with Parkinson’s disease and conventional or adaptive deep brain stimulation
Objective: To describe the activity of the subthalamic nucleus (STN) during wake and sleep in patients with Parkinson’s disease (PD) with conventional (cDBS) or adaptive…Enhancing Step Detection in Real-World Gait
Objective: To enhance accuracy and applicability of algorithms for step detection obtained from free-living gait accelerometer data in individuals with Parkinson’s Disease (PD). Background: When…Role of APOE Polymorphism and CSF Markers of AD Co-Pathology in the Cognitive Trajectories of Sporadic and Genetic Parkinson’s Disease: A Longitudinal Cohort Study
Objective: To evaluate if APOE genotype and CSF biomarkers of AD co-pathology are associated with distinct rates of cognitive decline in PD subtypes. Background: Cognitive…Reliability and Validity of In-home Tele-Neuropsychological Testing in Patients with Parkinson’s Disease: A Randomized Trial
Objective: To assess the reliability and diagnostic validity of in-home tele-neuropsychological testing (in-home tele-npt) in individuals with Parkinson’s disease (PD). Background: Neuropsychological testing is inaccessible…Machine-learning Prediction of Cognition in Parkinson’s disease: Benchmarking EEG Source Functional Connectivity and Structural MRI
Objective: To develop machine-learning neural biomarkers to predict cognition in Parkinson’s disease (PD). Background: Variable levels of cognitive impairment are found in PD[1,2], but optimal…Design of the Phase 2, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of ACP-204, a Novel 5-HT2A Inverse Agonist, in Adults With Lewy Body Dementia Psychosis
Objective: To present the design for a study of ACP-204 efficacy and safety in adults with Lewy body dementia psychosis (LBDP), including Parkinson’s disease dementia…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 181
- Next Page »